NICE backs Astellas’ Xtandi in pre-chemo patients, but J&J’s Zytiga isn’t so lucky

Carly Helfand

and Medivation's prostate cancer med has been coming up strong behind from Johnson & Johnson ever since hitting the market. And now, it's getting a boost in the U.K. that should help it gain more ground against its rival.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS